Hypertension (HTN) and atrial fibrillation (AF) often coexist in many patients. Myocardial fibrosis is common in both of them. Galectin 3 (LGAL3) is often used biomarker of cardiac fibrosis. The aim of this study is to assess the impact of HTN on clinical presentation and on the cardiac fibrosis in patients >55 years with AF after sinus rhythm restoration.Design and method:
Overall, 59 patients with AF and no history of cardiovascular (CV) diseases, after sinus rhythm restoration that were included in a clinical trial of one-year placebo-controlled treatment with spironolactone were analyzed in accordance to the presence or not of HTN. Other important demographic factors, cardiovascular risk profile including the presence of diabetes mellitus, dyslipidemia, hyperuricemia, etc., were also compared. Anthropometric, haemodynamic, and echocardiographic measures in both groups were evaluated. LGAL3 was assessed by ELISA method at baseline and after 12 months in 28 patients.Results:
The patients with HTN were the majority – 86%, with no gender difference. The mean age of the participants was 67.34 ± 7.22 years, with no significant difference between those with or without HTN. At baseline, the hypertensive patients were with significantly higher BMI (30.86 ± 6.14 vs 27.11 ± 4.19 kg/m2, p = 0.049), and had not significantly higher systolic and diastolic BP. They had lower ejection fraction (58.98 ± 6.39% vs 65.88 ± 4.59%, p = 0.005) and a trend to lower E/A ratio of the mitral blood flow (1.07 ± 0.55 vs 1.450.87, p = 0.138). Although the mean baseline LGAL3 was lower in the HTN group - 14.52 ± 5.20 vs 18.54 ± 15.48 ng/ml, the biomarker significantly increased after one year follow-up in this group, irrespective of their treatment. The LGAL3 in the HTN group increased from baseline to 1 year on average with 0.97 ± 3.13 ng/ml, while in non-HTN AF patients the mean difference decreased with 2.42 ± 4.97 ng/ml (p = 0.048).Conclusions:
The patients with HTN and AF had higher BMI and lower systolic function and left ventricular relaxation. Galectin-3 increased after one year in patients with HTN, nevertheless their treatment.